NasdaqGM:AXSMPharmaceuticals
Axsome Therapeutics (AXSM) Is Up 6.2% After Highlighting Key FDA Decision on Auvelity
Axsome Therapeutics recently highlighted the upcoming release of its first-quarter 2026 results on May 4 and the pending US Food and Drug Administration decision on Auvelity for agitation associated with Alzheimer's disease, a potential new indication for its central nervous system portfolio.
Analysts see the Alzheimer's agitation application for Auvelity as a potentially meaningful new revenue stream, given the high unmet medical need and expectations that the drug may avoid an added...